semaglutide menstruation and metformin improve menstrual cyclicity in overweight/obese women with polycystic ovary syndrome: a randomized How Semaglutide and Tirzepatide Affect
Description
J., Khutoryansky, N., Zdravkovic, M., Sprenger, C
Semaglutide is a GLP-1 receptor agonist initially developed as a medication for diabetes
2022;27:e13211
Every bite carries more weight
Preclinical research indicates that GIPR activation also modulates lipid metabolism in adipose tissue and contributes to weight reduction through mechanisms distinct from GLP-1R pathways
